To the full analysis
Caris Life Sciences stock: growth
CAICaris Life Sciences reported $812.03M in revenue for fiscal 2025, up 97% on the prior year, up 14.3% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.5%
per year from 2005 to 2025, per share −0.1%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
4.5%
per year from 2005 to 2025, per share −8.8%
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2019 | since 2014 | since 2005 | |
|---|---|---|---|
| Revenue | 14.3% | 13.6% | 14.5% |
| Revenue per share | −34.1% | −12.5% | −0.1% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | 4.5% |
| Free cash flow per share | no data | no data | −8.8% |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2005 | $61.59M | $9.99M | $29.06M |
| 2006 | $18.61M | $5.23M | −$37.48M |
| 2007 | $64.87M | $19.23M | −$219.93M |
| 2008 | $83.15M | −$26.95M | −$176.86M |
| 2009 | $65.26M | $13.56M | −$555K |
| 2010 | $77.9M | $28.38M | −$164.41M |
| 2011 | $125.71M | $50.19M | −$419.82M |
| 2012 | $173.93M | $63.47M | −$417.77M |
| 2013 | $212.41M | $63.93M | −$188.02M |
| 2014 | $227.59M | $60.27M | −$167.62M |
| 2015 | $249.67M | $26.84M | −$242.05M |
| 2016 | $294.35M | $6M | −$121.99M |
| 2017 | $348.39M | $72.06M | −$346.98M |
| 2018 | $432.1M | $78.6M | −$633.07M |
| 2019 | $416.54M | $31.01M | −$65.15M |
| 2020 | $294.01M | $27.73M | $57.57M |
| 2022 | $258.49M | −$320.83M | −$327.96M |
| 2023 | $306.13M | −$341.42M | −$298.42M |
| 2024 | $412.26M | −$281.89M | −$253.64M |
| 2025 | $812.03M | −$537.96M | $66.9M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 7 Aug 2026)
- Valuation signal Fairly valued since 13 Nov 2026, previously Overvalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.